Abstract 353P
Background
To date, there is limited information on Indian oncologists' views and experiences of geriatric oncology. This study aimed to explore the views of Indian oncologists regarding the perception of, and barriers to the incorporation of geriatric screening tools, GA and collaboration with geriatricians in routine clinical practice.
Methods
This was an anonymized cross-sectional survey. The online survey, based on a literature review and expert opinion, comprised 12 questions covering: (i) respondent characteristics, clinical practice environment and patient population; (ii) challenges and treatment decision-making factors in the management of older patients with cancer; and (iii) benefits of and barriers to the implementation of GA or geriatrician review in cancer care for older patients. Qualitative variables were reported as numbers (N) and percentages. Statistical analyses were performed using χ 2 or Fisher’s exact test. Results were considered statistically significant with p < 0.05. Statistical analyses were conducted using SPSS software (version 20).
Results
Between March 2019 and June 2019, 100 answers were collected. Only 74 centres (48%) had a geriatrics department and a mere 21 (14%) medical oncology departments had a person dedicated to GO. The vast majority (n = 100; 88%) had the perception that the number of elderly patients with cancer seen in clinical practice had increased. Eighteen (12%) oncologists had specific protocols and geriatric scales were used at 55 (31%) centres. Almost all (91%) claimed not to apply special management practices using specific tools for every geriatric patient. There was agreement that GO afforded certain potential advantages. Finally, 99% of the oncologists surveyed believed it and that training in GO had to be improved.
Conclusions
From the nationwide survey, we conclude that there is currently no defined care structure for elderly cancer patients. There is an increasing perception of the need for training in GO. This survey reflects a reality in which specific needs are perceived.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tata Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session